Adenoid Cystic Carcinoma (ACC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 

Adenoid cystic carcinoma (ACC) is a rare tumor that originates within secretory glands and accounts for a substantial portion of minor salivary, parotid, and submandibular gland malignancies. ACC can occur in other parts of the body, including the breast, skin, cervix in females, the prostate gland in males, and other areas. ACC tumors have a distinct histological pattern that consists of abnormal "nests" or cords of specific cells (epithelial cells) that surround and infiltrate ducts or glandular structures within the affected organ. Typically, these structures are filled with a mucous-like material or have abnormal fibrous membranes. Such characteristics are visible during a microscopic examination of tumor cells in a biopsy sample. The most common course of treatment for ACC is surgical excision, which is typically followed by external radiation of the surgical bed and the draining of the named nerves in the head and neck.

  • ACC incidence ranges from 0.5 to 0.72 cases per 100,000 population in the USA, with an 88.5% 5-year survival.

Thelansis’s “Adenoid Cystic Carcinoma (ACC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adenoid Cystic Carcinoma (ACC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Adenoid Cystic Carcinoma (ACC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Adenoid Cystic Carcinoma (ACC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Adenoid Cystic Carcinoma (ACC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033